VanEck Biotech ETF (NASDAQ:BBH) Short Interest Up 33.3% in November

VanEck Biotech ETF (NASDAQ:BBH) saw a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 800 shares, an increase of 33.3% from the October 31st total of 600 shares. Based on an average trading volume of 4,800 shares, the days-to-cover ratio is presently 0.2 days.

VanEck Biotech ETF Trading Up 0.2 %

Shares of BBH stock opened at $167.37 on Monday. The firm’s 50-day simple moving average is $171.70 and its 200-day simple moving average is $173.15. VanEck Biotech ETF has a 1-year low of $150.62 and a 1-year high of $183.64.

Hedge Funds Weigh In On VanEck Biotech ETF

A number of large investors have recently bought and sold shares of the stock. International Assets Investment Management LLC raised its holdings in shares of VanEck Biotech ETF by 10,376,390.9% in the 3rd quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock worth $202,475,000 after purchasing an additional 1,141,403 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in VanEck Biotech ETF by 5.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock worth $4,096,000 after purchasing an additional 1,334 shares in the last quarter. Jane Street Group LLC increased its position in VanEck Biotech ETF by 401.7% during the 3rd quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock worth $1,481,000 after purchasing an additional 6,684 shares in the last quarter. Atlas Capital Advisors LLC purchased a new position in VanEck Biotech ETF in the second quarter valued at approximately $960,000. Finally, Kovitz Investment Group Partners LLC lifted its position in VanEck Biotech ETF by 4.6% during the third quarter. Kovitz Investment Group Partners LLC now owns 3,186 shares of the company’s stock valued at $565,000 after buying an additional 141 shares in the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.